{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:31:42Z","timestamp":1791232302044,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jocn.2025.111584","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T03:15:39Z","timestamp":1756178139000},"page":"111584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Time-saved and time-invested with anti-amyloid treatments in early Alzheimer\u2019s disease: practical considerations"],"prefix":"10.1016","volume":"141","author":[{"given":"Rui","family":"Ara\u00fajo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Reis Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Nunes Rato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Massano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2025.111584_b0005","unstructured":"European Commission. (2024, April 22). https:\/\/ec.europa.eu\/newsroom\/sante\/items\/879055\/en. Accessed 3 May 2025."},{"issue":"1","key":"10.1016\/j.jocn.2025.111584_b0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.jocn.2025.111584_b0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jocn.2025.111584_b0020","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/alz.12959","article-title":"Expectations and clinical meaningfulness of randomized controlled trials","volume":"19","author":"Petersen","year":"2023","journal-title":"Alzheimer's Dementia"},{"issue":"4","key":"10.1016\/j.jocn.2025.111584_b0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-090403","article-title":"Cost-effectiveness analysis of aducanumab versus placebo for patients with mild cognitive impairment and mild Alzheimer's disease","volume":"15","author":"Xiong","year":"2025","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.jocn.2025.111584_b0030","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209218","article-title":"Cost-effectiveness of lecanemab for individuals with early-stage Alzheimer disease","volume":"102","author":"Nguyen","year":"2024","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jocn.2025.111584_b0035","doi-asserted-by":"crossref","first-page":"8162","DOI":"10.1002\/alz.14199","article-title":"Benefits and risks of FDA\u2010approved amyloid\u2010targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician\u2010patient engagement","volume":"20","author":"Rentz","year":"2024","journal-title":"Alzheimer's Dementia"},{"issue":"1","key":"10.1016\/j.jocn.2025.111584_b0040","article-title":"Assessing the clinical meaningfulness of slowing CDR\u2010SB progression with disease\u2010modifying therapies for Alzheimer's disease","volume":"11","author":"Hartz","year":"2025","journal-title":"Alzheimer's Dementia"},{"issue":"1","key":"10.1016\/j.jocn.2025.111584_b0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13195-024-01412-z","article-title":"The search for clarity regarding \u201cclinically meaningful outcomes\u201d in Alzheimer disease clinical trials: CLARITY-AD and beyond","volume":"16","author":"Tarawneh","year":"2024","journal-title":"Alzheimer's Res Ther"},{"issue":"5","key":"10.1016\/j.jocn.2025.111584_b0050","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.14283\/jpad.2024.81","article-title":"Medical costs and caregiver burden of delivering disease-modifying Alzheimer's treatments with different duration and route of administration","volume":"11","author":"Ozawa","year":"2024","journal-title":"J Prevent Alzheimer's Dis"},{"issue":"11","key":"10.1016\/j.jocn.2025.111584_b0055","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/oncolo\/oyae187","article-title":"Patients' considerations of time toxicity when assessing cancer treatments with marginal benefit","volume":"29","author":"Gupta","year":"2024","journal-title":"The Oncologist"},{"issue":"11","key":"10.1016\/j.jocn.2025.111584_b0060","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jocn.2025.111584_b0065","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.14283\/jpad.2024.159","article-title":"Initial experience with lecanemab and lessons learned in 71 patients in a regional medical center","volume":"11","author":"Shields","year":"2024","journal-title":"J Prevent Alzheimer's Dis"},{"issue":"5","key":"10.1016\/j.jocn.2025.111584_b0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.11711","article-title":"Disparities in early lecanemab uptake among US medicare beneficiaries","volume":"8","author":"Zhou","year":"2025","journal-title":"JAMA network open"},{"key":"10.1016\/j.jocn.2025.111584_b0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jocn.2025.111584_b0080","unstructured":"Drug Discovery World. (2025, June 24). NICE rejects Alzheimer\u2019s drugs for lack of cost-effectiveness. DDW-online. Retrieved August 15, 2025, from https:\/\/www.ddw-online.com\/nice-rejects-alzheimers-drugs-for-lack-of-cost-effectiveness-35411-202506\/."},{"issue":"9","key":"10.1016\/j.jocn.2025.111584_b0085","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1002\/alz.14162","article-title":"Design and validation of the ADNI MR protocol","volume":"20","author":"Arani","year":"2024","journal-title":"Alzheimer's Dementia"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825005570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825005570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T21:08:12Z","timestamp":1762290492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586825005570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":17,"alternative-id":["S0967586825005570"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111584","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time-saved and time-invested with anti-amyloid treatments in early Alzheimer\u2019s disease: practical considerations","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111584"}}